US cancer five-year survival reaches 71%, AACR progress report finds
Start here
The American Association for Cancer Research's Cancer Progress Report 2026 documents five decades of gains against cancer in the United States. Seventy-one percent of people with cancer now live at least five years after diagnosis, up from 49% in the late 1970s. Lung cancer five-year survival rose from 13% for those diagnosed between 1975 and 1979 to 29% between 2016 and 2022, and survival for lymphoid leukaemia in children and adolescents up to 19 climbed from 57% to 90%. Liver cancer survival has tripled to 22% since the mid-1990s. The report's figures stand as a record of progress; how the remaining gaps across malignancies will narrow is not addressed.
Written by a model from the reports · updated 6 days ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comAACR Issues 16th Annual Cancer Progress Report Spotlighting Vaccines, AI and Liquid Biopsy
The American Association for Cancer Research has released its 16th annual Cancer Progress Report, covering the 12 months from July 2025 to June 2026. Issued each September, the report reviews the past year in cancer research and care, and this edition highlights cancer vaccines, artificial intelligence and liquid biopsy. Its data come from the United States, but the report says the trends it describes are global.
- youtube.comAACR Cancer Progress Report 2026 Links Patient Stories to New Therapies Including Zongertinib and ONC201
AACR has released its Cancer Progress Report 2026, built around survivor narratives that trace journeys from diagnosis through clinical trials to treatment with new targeted therapies such as zongertinib and ONC201. The report frames sustained, stable federal research funding as central to rising cancer survival rates, and points to personalized vaccines and new targeted drugs as practice-changing. It includes one forward-looking mention of AI reducing complex data to better starting points for diagnosis and therapy.
- youtube.comAACR Congressional Briefing Covers Precision Medicine, RAS Inhibitors and Personalized Cancer Vaccines
An AACR briefing for US Congress, part of a 95-minute expert lecture, outlined progress in precision oncology: the first molecularly targeted therapy for diffuse midline glioma, protein-degrading agents, seven FDA-approved CAR-T therapies since 2017 including a first for marginal zone lymphoma, and KRAS inhibitors that nearly doubled survival in advanced pancreatic cancer in a Phase III trial. It also highlighted liquid biopsy, a positive Phase III trial of a personalized melanoma neoantigen vaccine, and rising early-onset colorectal cancer rates of more than 6% per year in the US from 2019 to 2023.
- mp.weixin.qq.comAACR Cancer Progress Report 2026: US Cancer Mortality Fell 35% From 1991 to 2024
The American Association for Cancer Research released the AACR Cancer Progress Report 2026, showing that overall cancer mortality in the United States fell 35% between 1991 and 2024. The report attributes the decline mainly to reduced smoking rates and the resulting drop in lung cancer deaths. The report also points to further anticancer advances ahead.
- nature.comThe top cancer success stories of the past 50 years, by the numbers
The American Association for Cancer Research's Cancer Progress Report 2026 finds that 71% of people with cancer in the United States now live at least five years after diagnosis, up from 49% in the late 1970s. Lung cancer five-year survival rose from 13% for those diagnosed between 1975 and 1979 to 29% between 2016 and 2022, while lymphoid leukaemia survival in children and adolescents up to 19 rose from 57% to 90%. Liver cancer survival has tripled to 22% since the mid-1990s, though gains remain uneven across malignancies.
Heat trend for this story
Heat now 0·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.